查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球上呼吸道疾病治療市場
市場調查報告書
商品編碼
1351035

2023-2030年全球上呼吸道疾病治療市場

Global Upper Respiratory Tract Disease Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

預計在預測期內（2023-2030年），全球上呼吸道疾病治療市場將以3.6%的年複合成長率成長。上呼吸道感染 (URTI) 是一種疾病，是由涉及人的上呼吸道（如鼻子、鼻竇、咽或喉）的急性感染引起的。感染常見包括鼻塞、喉嚨痛、扁桃體炎、咽炎、喉炎、中耳炎和普通感冒。可以使用多種藥物來治療這種疾病，針對細菌和病毒等致病病原體。越來越多的患有氣喘、充血性心臟衰竭和慢性阻塞性肺病的成年人患呼吸道合胞病毒感染的風險更高，導致市場成長。根據美國公共科學圖書館計算生物學的一項研究，URTD是由多種細菌和病毒引起的，感染的情況可以從輕度感冒到危及生命的肺炎。作為最常見的疾病之一，2019 年 URTI 的全球負擔估計為 172 億人。儘管大多數感染 URTI 的人表現出輕微症狀，但僅在美國，非流感相關病毒性 URTI 的經濟負擔估計高達 225 億美元，並且估計有 20 億美元用於 URTI 的非處方治療。

細分市場前景

全球上呼吸道疾病治療市場按類別、治療方法和藥物類別進行細分。根據類別，市場分為非處方藥和處方藥。根據治療方法，市場分為局部治療、止咳藥、鼻減充血劑等。此外，依藥物類別，市場分為非類固醇抗發炎藥、抗生素等。其中，非處方藥細分市場預計將佔據相當大的市場佔有率，因為它無需處方即可輕鬆獲得，並且可以有效治療

感染或細菌性疾病。由於上呼吸道感染以及治療這些感染的非處方藥物的需求不斷增加，醫師的家訪次數也有所增加。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • F. Hoffmann-La Roche Ltd
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Pfizer Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Teva Pharmaceutical Industries Ltd.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 全球上呼吸道疾病治療市場依類別
    • 場外交易
    • 處方
  • 按治療分類的全球上呼吸道疾病治療市場
    • 局部治療
    • 止咳
    • 鼻減充血劑
    • 其他（抗組織胺、癒創甘油醚和色甘酸）
  • 按藥物類別分類的全球上呼吸道疾病治療市場
    • 非類固醇抗發炎藥
    • 抗生素
    • 其他（布洛芬）

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Alcon, Inc.
  • AstraZeneca Plc
  • Cipla Limited
  • CSL Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Limited
  • Market positioning of vendors
  • Merck & Co., Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Sandoz, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
Product Code: OMR2027636

Title: Global Upper Respiratory Tract Disease Treatment Market Size, Share & Trends Analysis Report by Category (OTC and Prescription), by treatment (topical treatment, cough suppressant, nasal decongestant and other), and by drug class (NSAID, antibiotics and others),Forecast Period (2023-2030).

The global upper respiratory tract disease treatment market is anticipated to grow at a CAGR of 3.6% during the forecast period (2023-2030). upper respiratory tract infection (URTI) is an illness, which is the result of an acute infection involving a person's upper respiratory tract like the nose, sinuses, pharynx, or larynx. The infection commonly includes nasal obstruction, sore throat, tonsillitis, pharyngitis, laryngitis, otitis media, and the common cold. This can be treated using various drugs, targeting disease-causing pathogens like bacteria and viruses. Increasing number of Adults with asthma, congestive heart failure, and COPD are at higher risk of suffering from respiratory syncytial virus infection lead to the growth of the market. According to a study of plos computing biology US, URTD caused by a variety of bacteria and viruses, and the infection can vary from a mild cold to life-threatening pneumonia. Being one of the most common diseases, the global burden of URTI in 2019 is estimated to be 17.2 billion. Although a majority of individuals contracting URTIs present mild symptoms, the estimated economic burden of non-influenza related viral URTIs in the United States alone is estimated to be 22.5 billion USD and an estimated $2 billion is spent on over-the-counter treatments for URTIs.

Segmental Outlook

The global upper respiratory tract disease treatment market is segmented on the category, treatment, and drug class. Based on the category, the market is sub-segmented into OTC and Prescription. Based on the treatment, the market is sub-segmented into topical treatment, cough suppressant, nasal decongestant and other. Further, on the basis of drug class, the market is sub-segmented into NSAID, antibiotics and others. Among the category, the OTC sub-segment is anticipated to hold a considerable share of the market owing to its easy availability without any prescription and it is effective in treating

Inflectional or bacterial diseases. Also increase in the home visits by physicians due to upper respiratory tract infections and escalating demand for over the counter medicines to treat these infections.

The Antibiotic Sub-Segment is Anticipated to Hold a Considerable Share of the Global Upper Respiratory Tract Disease Treatment Market

Among the drug class, the antibiotic sub-segment is expected to hold a considerable share of the global upper respiratory tract disease market. The segmental growth is attributed to the growing cases of upper respiratory tract disease and lack of availability and affordability of doctors and proper medical prescription in many countries such as Africa, Sri Lanka, and Pakistan. Which lead to increase in demand for antibiotics owing to its easy availability of antibiotics to treat upper respiratory tract infections and their symptoms will drive the upper respiratory tract infection treatment market.

Regional Outlook

The global Upper Respiratory Tract Disease Treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to rise in demand due to increasing case of bacterial and viral diseases in the countries like china, India and Indonesia.

The North America Region is Expected to Grow at a Significant CAGR in the Global Upper Respiratory Tract Disease Treatment Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to increasing prevalence of upper respiratory tract infections in the region due to sudden climate changes and increasing consumption of cigarette. Owing to Increase in demand for Cough suppressants, nasal decongestants, and nasal washes. According to a report of national library of medicine US, in September 2022, chronic diseases associated with cigarette smoking include respiratory and cardiovascular diseases, cancers, and diabetes. An estimated 16 million US adults live with a smoking-related disease. Cigarette smoking can increase the risk of chronic disease and subsequent complications and can lead to overall reduced quality of life.

Hence, there is considerable shift of the country towards the adoption of the Upper Respiratory Tract Disease Treatment market solutions. The growing awareness regarding the treatment and the rising disposable income, especially in emerging economies, are expected to drive the industry growth.

Market Players Outlook

The major companies serving the upper respiratory tract disease treatment market include: AbbVie Inc., GlaxoSmithKline plc, Johnson & Johnson Pvt. Ltd., Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, Pfizer Inc. and ReViral Ltd. announced that the two companies have entered into a binding agreement under which Pfizer will acquire ReViral. ReViral is a clinical-stage biopharmaceutical company with a focus on finding, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global upper respiratory tract disease treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. F. Hoffmann-La Roche Ltd
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Pfizer Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Teva Pharmaceutical Industries Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Upper respiratory tract disease Treatment Market by Category
    • 4.1.1. OTC
    • 4.1.2. Prescription
  • 4.2. Global Upper respiratory tract disease Treatment Market by Treatment
    • 4.2.1. Topical treatment
    • 4.2.2. Cough Suppressant
    • 4.2.3. Nasal Decongestant
    • 4.2.4. Others (Antihistamines, Guaifenesin, and Cromolyn)
  • 4.3. Global Upper respiratory tract disease Treatment Market by Drug class
    • 4.3.1. NSAID
    • 4.3.2. Antibiotics
    • 4.3.3. Others (Ibuprofen)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Alcon, Inc.
  • 6.2. AstraZeneca Plc
  • 6.3. Cipla Limited
  • 6.4. CSL Ltd.
  • 6.5. Dr. Reddy's Laboratories Ltd.
  • 6.6. F. Hoffmann-La Roche Ltd
  • 6.7. GlaxoSmithKline plc
  • 6.8. Lupin Limited
  • 6.9. Market positioning of vendors
  • 6.10. Merck & Co., Inc.
  • 6.11. Novartis AG
  • 6.12. Regeneron Pharmaceuticals Inc.
  • 6.13. Sandoz, Inc.
  • 6.14. Sanofi
  • 6.15. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 2. GLOBAL OTC FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL PRESCRIPTION UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 5. GLOBAL TOPICAL TREATMENT FOR UPPER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 6. GLOBAL COUGH SUPPRESSANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL NASAL DECONGESTANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 8. GLOBAL OTHER TREATMENT FOR UPPER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 9. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 10. GLOBAL NSAID FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL ANTIBIOTICS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT FOR AUTOMOTIVE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 12. GLOBAL OTHER DRUGS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT FOR HEALTHCARE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 18. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 21. EUROPEAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 22. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 26. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY CATEGORY, 2022 VS 2030 (%)
  • 2. GLOBAL OTC FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PRESCRIPTION FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY TREATMENT, 2022 VS 2030 (%)
  • 5. GLOBAL TOPICAL TREATMENT FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL COUGH SUPPRESSANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL NASAL DECONGESTANT UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL OTHER TREATMENTS FOR UPPER RESPIRATORY TRACT DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 10. GLOBAL NSAID FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT ON BFSI MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL ANTIBIOTICS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL OTHER DRUGS FOR UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. US UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. CANADA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. UK UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. FRANCE UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. GERMANY UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. ITALY UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. SPAIN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. REST OF EUROPE UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. INDIA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. CHINA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. JAPAN UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. SOUTH KOREA UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. REST OF ASIA-PACIFIC UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD UPPER RESPIRATORY TRACT DISEASE TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)